Brokers Set Expectations for TG Therapeutics FY2026 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at Cantor Fitzgerald cut their FY2026 earnings per share (EPS) estimates for shares of TG Therapeutics in a report released on Tuesday, November 4th. Cantor Fitzgerald analyst P. Agrawal now expects that the biopharmaceutical company will post earnings of $1.63 per share for the year, down from their previous forecast of $1.79. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

A number of other research firms have also issued reports on TGTX. B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday. HC Wainwright assumed coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday. Finally, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

TG Therapeutics Price Performance

TGTX stock opened at $33.81 on Wednesday. TG Therapeutics has a 1 year low of $23.60 and a 1 year high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock’s 50 day moving average price is $33.66 and its 200 day moving average price is $34.75. The firm has a market cap of $5.36 billion, a P/E ratio of 91.38 and a beta of 1.97.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. During the same quarter in the previous year, the company earned $0.02 EPS. The company’s quarterly revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.64% of the stock is currently owned by insiders.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock worth $274,180,000 after buying an additional 184,339 shares during the last quarter. Geode Capital Management LLC increased its holdings in TG Therapeutics by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock valued at $126,033,000 after purchasing an additional 207,890 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares in the last quarter. Hood River Capital Management LLC raised its position in TG Therapeutics by 0.7% in the second quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock valued at $56,415,000 after purchasing an additional 11,018 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of TG Therapeutics by 1,809.9% in the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock worth $47,830,000 after buying an additional 1,149,526 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.